References

  1. Kaiser Family Foundation. Prescription Drug Trends May 2010 Update. Available from: http://www.kff.org/rxdrugs/upload/3057_07.pdf. Cited 12 December 2010.

  2. Wazana A. Physicians and the Pharmaceutical Industry - Is a Gift Ever Just a Gift? JAMA. 2000;283(3):373-80. Google Scholar

  3. Kisa S. Factors that Influence Prescribing Decisions among Turkish Physicians. Clinical Research & Regulatory Affairs. 2006; 23(3/4):177-89. PubMed | Google Scholar

  4. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement. BMJ. 2003;326(7400):1189-92. PubMed | Google Scholar

  5. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996; 5(4):201-6. PubMed | Google Scholar

  6. Bohner G, Wanke M. Attitudes and attitude change. East Sussex: Psychology Press. 2002. PubMed | Google Scholar

  7. Cialdini RB, Petty RE, Cacioppo JT. Attitude and attitude change. Annual Review of Psychology. 1981;32:357-404. PubMed | Google Scholar

  8. Roughead L. The pharmaceutical representative and medical practitioner encounter: Implications for quality use of medicines (MSc thesis). School of Pharmacy, University of South Australia, 1996.

  9. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2003;3(3):39-46. PubMed | Google Scholar

  10. Bem DJ. Self-Perception: An Alternative Interpretation of Cognitive Dissonance Phenomena. Psychol Rev. 1967 May;74(3):183-200. PubMed | Google Scholar

  11. Muijrers PE, Grol RP, Sijbrandij J, Janknegt R, Knottnerus JA. Differences in prescribing between GPs. Impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives. Fam Pract. 2005 Dec;22(6):624-30. PubMed | Google Scholar

  12. Carlzon D, Gustafsson L, Eriksson A, Rigner K, Sundstrom A, Wallerstedt S. Characteristics of primary health care units with focus on drug information from the pharmaceutical industry and adherence to prescribing objectives: a cross-sectional study. BMC Clinical Pharmacology. 2010;10(1):4. PubMed | Google Scholar

  13. van Duijn HJ, Kuyvenhoven MM, Schellevis FG, Verheij TJ. Determinants of prescribing of second-choice antibiotics for upper and lower respiratory tract episodes in Dutch general practice. J Antimicrob Chemother. 2005;56(2):420-2. PubMed | Google Scholar

  14. Alssageer MA, Kowalski SR. A survey of pharmaceutical company representative interactions with doctors in Libya. Libyan J Med. 2012;7. PubMed | Google Scholar

  15. Leckie GJ, Pettigrew KE, Sylvain C. Modeling the Information Seeking of Professionals: A General Model Derived from Research on Engineers, Health Care Professionals, and Lawyers. The Library Quarterly .1996;66(2):161-193.. PubMed | Google Scholar

  16. Ben Abdelaziz A, Harrabi I, Rahmani S, Ghedira A, Gaha K, Ghannem H. Attitudes of general practitioners to pharmaceutical sales representatives in Sousse. East Mediterr Health J. 2003;9:1075-83. PubMed | Google Scholar

  17. Layton MR, Sritanyarat W, Chadbunchachai S, Wertheimer AI. Sources of information for new drugs among physicians in Thailand. Pharm World Sci. 2007;29(6):619-27. PubMed | Google Scholar

  18. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract. 2003;20(1):61-8. PubMed | Google Scholar

  19. McCue JD, Hansen CJ, Gal P Physicians' opinions of the accuracy, accessibility, and frequency of use of ten sources of new drug information. South Med J. 1986;79(4):441-3. Google Scholar

  20. Kale R. Health information for the developing world. BMJ. 1994;309(6959):939?942. PubMed | Google Scholar

  21. Lexchin J. Deception by design: pharmaceutical promotion in the third world. Kaur SR, ed. Penang: Consumers International, 1995.

  22. Jafar TH, Jessani S, Jafary FH, Ishaq M, Orakzai R, Orakzai S et al. General practitioners' approach to hypertension in urban Pakistan: disturbing trends in practice. Circulation. 2005;111(10):1278-83. PubMed | Google Scholar

  23. Caamaño F, Figueiras A, Gestal-Otero JJ. Influence of commercial information on prescription quantity in primary care. Eur J Public Health. 2002;12(3):187-91. PubMed | Google Scholar

  24. McGettigan P, Golden J, Fryer J, Chan R, Feely J. Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message.Br J Clin Pharmacol. 2001;51(2):184-9. PubMed | Google Scholar

  25. Oshikoya KA, Oreagba I, Adeyemi O. Sources of drug information and their influence on the prescribing behaviour of doctors in a teaching hospital in Ibadan, Nigeria. Pan Afr Med J. 2011;9:13. PubMed | Google Scholar

  26. Magzoub MA, Neyaz Y, Khoja T, Qureshi NA, Haycox A, Walley T. Determinants of physicians' medication prescribing behaviour in primary care in Riyadh City, Saudi Arabia. East Mediterr Health J. 2011;17(2):160-6. PubMed | Google Scholar

  27. Gambrill J, Bridges-Webb C. Use of sources of therapeutic and prescribing information by general practitioners. Aust Fam Physician. 1980;9(7):482-4. PubMed | Google Scholar

  28. Figueiras A, Caamaño F, Gestal-Otero JJ. Influence of physician's education, drug information and medical-care settings on the quality of drugs prescribed. Eur J Clin Pharmacol. 2000;56(9-10):747-53. PubMed | Google Scholar

  29. Lexchin J. Prescribing by canadian general practitioners: review of the english language literature. Can Fam Physician. 1990;36:465-70. PubMed | Google Scholar

  30. Mapes R. Aspects of British general practitioners' prescribing. Med Care. 1977 May;15(5):371-81. PubMed | Google Scholar

  31. Strickland-Hodge B, Jepson MH Identification and characterization of early and late prescribers in general practice. J R Soc Med. 1982 May;75(5):341-5. Google Scholar

  32. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110(7):551-7. PubMed | Google Scholar

  33. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA. 1990 Oct 3;264(13):1693-7. PubMed | Google Scholar

  34. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract. 1994;44(382):220-3. PubMed | Google Scholar

  35. Aldir RE, Jarjoura D, Phinney M, Poordad F, Gutierrez R, Marnejon T et al. Practicing and resident physicians' views on pharmaceutical companies. J Contin Educ Health Prof. 1996;16: 25?32. PubMed | Google Scholar

  36. Pharmaceutical Research and Manufacturers of America PhRMA code on interactions with healthcare professionals. Washington, DC: PhRMA, 2002, http://www.phrma.org/files/phrma%20code.pdf. Accessed 19 July 2006.

  37. American Medical Association. Ethical Guidelines for Gifts to Physicians from Industry.1990. Available from: http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics/opinion8061.page. Accessed 14 March 2013.

  38. Burashnikova IS, Ziganshin AU, Ziganshina LE. Attitudes to pharmaceutical promotion techniques among healthcare professionals in the Republic of Tatarstan, Russia. International Journal of Risk & Safety in Medicine. 2008;20(1/2)57-7. PubMed | Google Scholar

  39. Haayer F. Rational Prescribing and Sources of Information. Social Science & Medicine.1982;16(23):2017-2023. PubMed | Google Scholar

  40. Lieb K, Brandtönies S. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives. Dtsch Arztebl Int. 2010;107(22):392-8. PubMed | Google Scholar

  41. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290(2):252-5. PubMed | Google Scholar

  42. Sagarin BJ, Cialdini RB, Rice WE, Serna SB. Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion. J Pers Soc Psychol. 2002;83(3):526-41. PubMed | Google Scholar

  43. Weinstein ND, Lyon JE. Mindset, optimistic bias about personal risk and health-protective behaviour. British Journal of Health Psychology. 1999;4(4):289-300. PubMed | Google Scholar

  44. Friestad M, Wright P. The Persuasion Knowledge Model: How People Cope with Persuasion Attempts. Journal of Consumer Research, 1994;21(1):1-31. Google Scholar

  45. Giarlo M. The role of skepticism in human-information behavior: a cognitive-affective analysis. Library Student Journal 2006. Available from: http://www.librarystudentjournal.org/index.php/lsj/article/view/24/16. Accessed 14 March 2013. PubMed | Google Scholar

  46. Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med. 1997;12(10):639-42. PubMed | Google Scholar

  47. Spurling G, Mansfield P. General practitioners and pharmaceutical sales representatives: quality improvement research. Qual Saf Health Care. 2007;16(4):266-70. PubMed | Google Scholar

  48. Mustafa AA, Kowalski S. A need for the standardization of the pharmaceutical sector in Libya. Libyan J Med. 2010;5:5440. PubMed | Google Scholar

  49. World Health Organization. Ethical criteria for medical drug promotion. http://www.who.int/medicinedocs. Accessed 3 August 2009.